Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase EARLY_PHASE1 1Phase 1/2 1

Status

Unknown 1Recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 1Gastrointestinal 1

Conditions

Uterine Cervical Dysplasia 1Squamous Intraepithelial Lesions 1Carcinoma, Hepatocellular 1

Interventions

Cisplatin 1519Carboplatin 1420Cyclophosphamide 1360Gemcitabine 1235Bevacizumab 1226Paclitaxel 1211Radiotherapy 1176Docetaxel 1080pembrolizumab 1028Oxaliplatin 936Capecitabine 901Fluorouracil 833Rituximab 729Doxorubicin 683Nivolumab 679Dexamethasone 666Etoposide 660Irinotecan 622Leucovorin 575Pemetrexed 510Drug Therapy 493Cetuximab 483Trastuzumab 469Cytarabine 466Magnetic Resonance Spectroscopy 458Filgrastim 446Prednisone 433Lenalidomide 409Specimen Handling 408Temozolomide 400

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Antigens × Clear all
NCT07174570 2026-01-28

Celecoxib, Durvalumab and Tremelimumab for the Treatment of Patients With Advanced or Metastatic Liver Cancer

Emory University

Phase 2 Recruiting
39 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT02576561 2017-10-25

Safety and Efficacy Study of TVGV-1 Vaccine to Treat HPV Induced Cervical HSIL

THEVAX Genetics Vaccine

Phase 2 Unknown
10 enrolled
Gynecologic

Squamous Intraepithelial Lesions, Uterine Cervical Dysplasia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡